5 hours Ago By ABMN Staff
HB Wealth Management LLC increased its holdings in Novartis AG ( NYSE:NVS – Free Report ) by 8.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,744 shares of the company’s stock after buying an additional 534 shares during the period.
HB Wealth Management LLC’s holdings in Novartis were worth $656,000 as of its most recent SEC filing. A number of other hedge funds have also bought and sold shares of the business. Legacy Investment Solutions LLC bought a new position in shares of Novartis in the third quarter worth $28,000.
Fortitude Family Office LLC boosted its position in shares of Novartis by 503.8% in the third quarter. Fortitude Family Office LLC now owns 320 shares of the company’s stock valued at $37,000 after acquiring an additional 267 shares during the period.
Clean Yield Group bought a new stake in Novartis during the 3rd quarter worth approximately $43,000. Brooklyn Investment Group purchased a new stake in Novartis in the 4th quarter worth approximately $55,000. Finally, Beaird Harris Wealth Management LLC boosted its holdings in Novartis by 280.
5% in the 3rd quarter. Beaird Harris Wealth Management LLC now owns 704 shares of the company’s stock valued at $81,000 after purchasing an additional 519 shares during the period. 13.
12% of the stock is currently owned by hedge funds and other institutional investors. Novartis Trading Up 2.2 % Shares of NVS opened at $99.
69 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.
90 and a current ratio of 1.11. Novartis AG has a fifty-two week low of $92.
35 and a fifty-two week high of $120.92. The firm has a 50 day moving average price of $100.
44 and a 200-day moving average price of $108.94. The firm has a market cap of $203.
76 billion, a price-to-earnings ratio of 11.58, a PEG ratio of 1.34 and a beta of 0.
57. Wall Street Analysts Forecast Growth A number of brokerages recently issued reports on NVS. BMO Capital Markets increased their price objective on Novartis from $118.
00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th.
Finally, HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Two analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. Based on data from MarketBeat, Novartis currently has an average rating of “Hold” and a consensus target price of $121.
50. View Our Latest Stock Analysis on NVS Novartis Company Profile ( Free Report ) Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians.
It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Read More Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG ( NYSE:NVS – Free Report ).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter ..
